Related Experiment Video
Updated: Oct 16, 2025
08:17
Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis
Published on: February 23, 2024
4.8K
Serum YKL-40 levels in patients with multiple sclerosis
Ahmet Dönder1, Hasan Hüseyin Özdemir2
1Mardin Artuklu University, Vocational School of Health Services, Department of Medical Laboratory, Mardin, Turkey.
Arquivos De Neuro-Psiquiatria
|October 20, 2021
Summary
Serum YKL-40 levels are elevated in early stages of Multiple Sclerosis (MS) and Clinically Isolated Syndrome (CIS). These findings suggest YKL-40 may serve as a valuable biomarker for MS-related inflammation.
Area of Science:
- Neuroimmunology
- Biomarker Discovery
- Inflammatory Diseases
Background:
- Multiple Sclerosis (MS) is a chronic central nervous system inflammatory disease.
- YKL-40 protein is involved in immune regulation and secreted by inflammatory cells.
Purpose of the Study:
- Investigate serum YKL-40 levels in patients with Clinically Isolated Syndrome (CIS) and MS.
- Determine the potential of YKL-40 as a biomarker for MS.
Main Methods:
- Enzyme-linked immunosorbent assays (ELISA) were used to measure serum YKL-40 levels.
- Participants included patients with CIS (n=20), relapsing-remitting MS (RRMS, n=39), and healthy controls (n=35).
Main Results:
- Serum YKL-40 levels were significantly higher in CIS and RRMS patients compared to controls (p < 0.001).
- Elevated YKL-40 levels were observed even in the early stages (CIS).
- YKL-40 levels in RRMS correlated with disability scores and age (p < 0.05).
Conclusions:
- YKL-40 may be a useful marker for the inflammatory process in MS.
- Elevated YKL-40 suggests its involvement early in the disease course.
